TwoKnct Media Publishing Ltd·Oct 11From Lab to Commercial Manufacturing: Why Pharmaceutical Technology Transfer Is a Critical Success…How pharmaceutical companies can bridge the gap between process development and commercial production through robust technology transfer…
Andrew Hillman | Legal Strategist in Dallas, Texas·Sep 27Single-Cell Sequencing Frameworks Unlocking Complex Genomic MechanismsIntroduction
Andrew Hillman | Legal Strategist in Dallas, Texas·Sep 13Recombinant DNA Innovations Driving Next-Generation Biopharmaceutical ProductionIntroduction
Anabiotec·Sep 2Potency assay development for biopharmaceuticals: From identification of mechanism-of-action to GMP…A therapeutic protein can sit at the correct concentration, pass every identity and purity test, and still fail to produce the effect it…
InZS AssociatesbyZS·Jul 17Why biopharma launch performance depends on stronger operating systemsFor many biopharma launch teams, readiness can look convincing from the inside. Milestones are tracked, dashboards are reviewed…
Jane Lee·Jul 2NAMS: In silico and in vitro approaches for Drug DevelopmentThe FDA has set forth new regulatory guidances around NAMS.
Liran Belenzon·Mar 20Five Shifts Defining the Next Phase of Drug DiscoveryFor decades, drug discovery has followed a familiar pattern. Generate hypotheses. Run experiments. Analyze results. Repeat. Progress came…
SHUVO KUMAR DASH (胡鹏达）·Mar 19Studying Biopharma in China: What It Actually Feels LikeI didn’t come to China just to study biopharmaceutical science.
Liran Belenzon·Jan 27The “Electric” Era of Biology: Why the New Bottleneck is Quality, Not IdeasAI is the new electricity. Just as the electrification of the early 20th century didn’t just give us better candles but fundamentally…
Liran Belenzon·Jan 17AI in Drug Discovery: 10 Lessons from the Front Lines of BiopharmaOver the past six months, I’ve spent hundreds of hours in rooms where the future of biopharma R&D is being negotiated. From deep-dive…A response icon1A response icon1
